EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.

Sarmad Sadeghi David I QuinnTanya DorffSumanta Kumar Pal Susan GroshenDenice Tsao-WeiRahul A Parikh Michael DevittMamta ParikhAlexandra JackovichNora RuelNicholas J VogelzangEarle BurgessImran SiddiqiInderbir S GillPrimo N LaraRobert DreicerParkash S Gill

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

The combination of sEphB4-HSA and pembrolizumab appears synergistic with improved OS and ORR compared with historical data for programmed death 1/programmed death ligand 1 monotherapy.

Keyphrases

advanced non small cell lung cancer
squamous cell carcinoma
small cell lung cancer
electronic health record
combination therapy
big data
cancer therapy
open label
epidermal growth factor receptor
data analysis
deep learning